Evidence map›Paper›PMID 33745341›Full record

ArticleCell transplantation

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas.

Gu Zhenyang, Li Nainong, Wu Xiaoxiong, Wang Maihong, Fu Xiaorui, Wang Zhao, Ren Hanyun, Li Yuhang, Li Xiaofan, Wu Yamei and 7 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Gu ZhenyangDepartment of Hematology, Chinese PLA General Hospital, Beijing, China.ORCID 0000-0003-0463-5065
Li NainongDepartment of Hematology, Fujian Institute of Hematology, Fuzhou, China.
Wu XiaoxiongDepartment of Hematology, The Forth Medical Center of PLA General Hospital, Beijing, China.
Wang MaihongCenter of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Fu XiaoruiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wang ZhaoDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ren HanyunDepartment of Hematology, Peking University First Hospital, Beijing, China.
Li YuhangDepartment of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Li XiaofanDepartment of Hematology, Fujian Institute of Hematology, Fuzhou, China.ORCID 0000-0002-6460-7210
Wu YameiDepartment of Hematology, The Forth Medical Center of PLA General Hospital, Beijing, China.
Liu YaoCenter of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Zhang MingzhiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wang YiniDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Liu DaihongDepartment of Hematology, Chinese PLA General Hospital, Beijing, China.
Dong YujunDepartment of Hematology, Peking University First Hospital, Beijing, China.
Hu LiangdingDepartment of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Huang WenrongDepartment of Hematology, Chinese PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNArmy Medical University · CNCapital Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CNFujian Institute of Microbiology · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of HLA-haploidentical allogeneic hematopoietic stem-cell transplantation (Haplo-HSCT) is increasing. Comparative studies about Haplo-HSCT versus allo-HSCT with HLA-matched sibling donors (MSD-HSCT) have been tried in leukemias and B-cell lymphomas. Few studies were reported in Peripheral T-cell lymphomas (PTCLs). We performed a multicenter retrospective study about 52 patients with PTCLs undergoing Haplo-HSCT (

Indexed as

AdolescentAdultHumansLymphoma, T-Cell, PeripheralMiddle AgedRetrospective StudiesSiblingsTransplantation, HaploidenticalYoung Adultallo-HSCTantithymocyte globulinhaploidentical donorHLA-matched sibling donorperipheral t-cell lymphoma

Identifiers

PMID33745341
PMCPMC7989122
OpenAlexW3137891075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.